Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Oncaspar. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Pegaspargase (sold as Oncaspar), first approved Feb 1, 1994, with 2 new uses approved and 0 published complete response letters.
First approved: Feb 1, 1994
Applications: 1
New uses approved: 2
Complete response letters: 0
Medicare spending, 2025: $1.8M
First approved in the EU: Jan 14, 2016
First approved in Japan: Jun 26, 2023
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 353 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Oncaspar, new ingredientA drug with a new active ingredient indicated for the treatment of acute lymphocytic leukemia and malignant lymphoma. · Nihon Servier Co., Ltd. · Jun 26, 2023
Clinical Trials
64 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
